Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Trial Identifier: D3250C00059
Sponsor: AstraZeneca
Start Date: October 2019
Primary Completion Date: September 2026
Study Completion Date: September 2026
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Calgary, AB, CA, T2N 4Z6
DK Aarhus N, DK, 8200
DK Ålborg, DK, 9000
DK Hvidovre, DK, 2650
DK København, DK, 2400
DK Naestved, DK, 4700
DK Odense C, DK, 5000
DK Vejle, DK, 7100
GB Cambridge, GB, CB2 2QQ
GB Headington, GB, OX3 9DU
GB Leicester, GB, LE3 9QP
GB Liverpool, GB, L7 8XP
GB London, GB, W1G 8HU
GB Wythenshawe, GB, M23 9LT
SE Göteborg, SE, 413 45
SE Lund, SE, 22185
US, AL Birmingham, AL, US, 35209
US, CA Los Angeles, CA, US, 90033
US, FL Jacksonville, FL, US, 32204
US, FL Miami, FL, US, 33166
US, GA Snellville, GA, US, 30078
US, IA Iowa City, IA, US, 52242
US, IN Indianapolis, IN, US, 46268
US, KS Kansas City, KS, US, 66160
US, MI Ann Arbor, MI, US, 48109
US, MI Bloomfield Hills, MI, US, 48301
US, MN Rochester, MN, US, 55905
US, MO Saint Louis, MO, US, 63156
US, NC New Bern, NC, US, 28562
US, NC Winston-Salem, NC, US, 27104
US, NY Maspeth, NY, US, 11378
US, PA Pittsburgh, PA, US, 15213
US, TX Galveston, TX, US, 77555
US, TX Lewisville, TX, US, 75067
US, TX Mansfield, TX, US, 76063